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Global Trends in the Etiology and
Incidence of HCC
Hepatocellular carcinoma (HCC) is the 5th most com-
mon cancer in men and 8th in women in the world,
with an estimated 0.5–1 million new cases per year.1,2
Overall, 75–80% of global HCC cases are attributable
to persistent viral infections with either hepatitis B
virus (HBV) (50–55%) or hepatitis C virus (HCV)
(25–30%).3 However, strong geographic correlations
have been found between the incidence of HCC and
the prevalence of hepatitis B surface antigen (HBsAg)
or antibody to hepatitis C virus (anti-HCV).3–11 For
example, in HBV-endemic areas such as Taiwan, chronic
HBV infection has the strongest association with the
development of HCC and accounts for 75–80% of all
HCC cases.3–6 But in certain parts of Southern Taiwan
where chronic HCV infection is prevalent, evidence
of chronic HCV infection is found in 30–50% of
HCC cases.3–6
Geographical variability in the incidence of HCC
has been noted in recent decades, which is largely
explained by the changing distribution and the natu-
ral history of HBV and HCV infection. HCC is the
first human cancer amenable to prevention by using
HBV vaccines. From a global perspective, the burden
of chronic HBV infection should begin to decline
because of the increasing utilization of HBV immuniza-
tion since the early 1980s.12,13 Recent studies demon-
strated that the Taiwanese mass vaccination program
against HBV has significantly reduced the carrier rate
of HBsAg in children and adolescents and, as anti-
cipated, the incidence of childhood HCC.14,15 After
universal hepatitis B immunization in Taiwan, the aver-
age annual incidence of HCC in children 6–14 years of
age declined gradually (0.70 per 100,000 children in
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1981–1986, 0.57 in 1986–1990, and 0.36 in 1990–
1994). Nevertheless, a substantial decrease in HCC inci-
dence in adults may be observed 3–4 decades later.16,17
Similar effects will be seen in other HBV-endemic
areas.
In contrast, the incidence of HCC has risen in the
past 10–20 years in several developed countries such as
the United States, Japan, England, and France where
HBV is not endemic.17–26 Although the reasons for
the trend are not clear, a recent review suggested that
a cohort effect related to HCV infection may likely
contribute to the increasing disease burden in these
countries.17
Viral Factors in HBV-related HCC
Chronic infection with HBV is a major risk factor for
the development of HCC. The hepatocarcinogenesis
in HBV infection has been extensively analyzed, and
multiple factors appear to play a role. A major factor is
chronic necroinflammation and subsequent fibrosis/
liver cell proliferation. Nevertheless, HCC only occurs
in a small proportion of HBsAg carriers. Since the hepa-
tocarcinogenic process involves the interplay between
HBV and host hepatocytes, both genomes may con-
tribute to the final pathogenic outcomes, either indi-
vidually or synergistically. It is therefore reasonable to
speculate that apart from host factors, viral factors are
very likely involved in HBV-related hepatocarcino-
genesis. In the following section, we will summarize
the current understanding on the role of viral proteins
and viral genomic variants in hepatocarcinogenesis.
HBV proteins associated with
hepatocarcinogenesis
In addition to carcinogenic events indirectly produced
by decades of chronic inflammation accompanied by
persistent necrosis and regeneration, HBV may encode
oncogenic viral proteins that possibly contribute to
hepatocarcinogenesis. For example, HBx is a well-
known viral non-structural gene that operates as a mul-
tifunctional regulator modulating gene transcription,
cell responses to genotoxic stress, protein degrada-
tion, apoptosis, and several signaling pathways.27–30
While the specific mechanisms are still unknown, its
critical role in liver malignant transformation has been
clearly demonstrated by transgenic mice with HBx
overexpression.31,32 Recently, the deletion at the pre-
S region of HBsAg has been identified to be more
prevalent in patients with progressive liver diseases than
in inactive carriers.33 The resulting truncated HBsAg
is found to accumulate in endoplasmic reticulum (ER)
and induce ER stress;34 however, its significance in
hepatocarcinogenesis warrants further clarification.
Role of HBV genotype, basal core promoter
(BCP) mutation and viral load in
hepatocarcinogenesis
In addition to viral oncogenic proteins, several viral
factors, including genotype, BCP mutation, and viral
load have been confirmed to be associated with hepa-
tocarcinogensis. Based on genomic sequence diver-
gence,35,36 there are 8 HBV genotypes (A–H) with
distinct geographical and ethnic distributions: geno-
types A and D prevail in Africa, Europe, and India;
genotypes B and C in Asia; genotype E only in West
Africa; and genotype F in Central and South America.37
HBV genotype has been shown to affect clinical out-
come and treatment responses. In Asia, genotype C 
is found to be more commonly associated with severe
liver diseases, liver cirrhosis, and HCC compared with
genotype B;28,31–34,38 in Western countries, genotype D
is more associated with severe liver disease and a higher
incidence of HCC than genotype A.39 Intriguingly, in
a large Taiwanese community cohort, the risk of HCC
starts to increase when viral load is greater than 10,000
copies or 2,000 IU/mL.38 In addition to viral geno-
type, specific viral genomic mutations also correlate
with HCC risk, particularly BCP T1762/A1764 muta-
tion.40,41 Nevertheless, these correlations need to be
confirmed by prospective cohort studies and await
further in vitro functional investigations.
Integrated analysis of HBV factors in HCC
In previous studies, genotype C, BCP T1762/A1764
mutation, and high viral loads have been shown to
carry an increased risk of HCC.38,40,42,43 However,
confounders may exist when analyzing only one or
few viral factors each time. In our cross-sectional ret-
rospective hospital-based study, we comprehensively
investigated the independent and interactive effects 
of each known viral factor on the development of
HCC.44 We found that advanced age, male gender,
precore A1896 mutation, BCP T1762/A1764 muta-
tion, and viral load >105 copies/mL were independently
associated with the development of HCC. Compared
with a viral load < 105 copies/mL and BCP A1762/
G1764 wild-type strain, the adjusted odds ratio of HCC
development was >30 in patients with a viral load >105
copies/mL and BCP T1762/A1764 mutant.
Viral factors in young-onset HCC
A previous study revealed that age-related differences
in the clinicopathologic characteristics of HCC patients
existed.45 However, little is known about the role of
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viral factors in the carcinogenesis of HCC in young
people. To clarify this issue, 183 HBV-related HCC
patients and 202 HBV carriers were enrolled.46 We
compared the serum viral loads in young (≤ 40 years
of age) and old (> 40 years of age) age groups and
showed that high serum HBV DNA levels were asso-
ciated with the development of HCC in old patients
rather than young patients. In addition, our previous
study demonstrated that genotype B was significantly
more common in patients with HCC aged < 50 years
compared with age-matched inactive carriers in Taiwan
(80% vs. 52%; p = 0.03).40 This predominance was
even more remarkable in younger patients with HCC,
being 90% in those aged < 35 years, and most were
non-cirrhotic. These data suggested that certain geno-
type B HBVs may be associated with the development
of HCC in young non-cirrhotic carriers.40 Similar find-
ings were reported in Taiwanese pediatric patients.47
Among 460 HBV carrier children being followed up
to 15 years, 26 children with HBV-related HCC were
documented, and genotype B was the major genotype
(74%). Hence, viral factors in association with the
development of HBV-related HCC in young patients
are different from their old-aged counterparts.
Viral factors in non-cirrhotic HCC
Studying HBV-related non-cirrhotic HCC may help
clarify the effect of viral factors in HCC development.
In a hospital-based age- and genotype-matched set-
ting, we examined the role of BCP T1762/A1764
mutation, precore A1896 mutation, and serum viral
load in non-cirrhotic hepatocarcinogenesis by com-
paring 44 patients with HBV-related non-cirrhotic
HCC, 45 with chronic hepatitis B, and 42 with HBV-
related cirrhotic HCC.48 By multiple logistic regression
analysis, male gender, BCP T1762/A1764 mutation,
and viral load > 105 copies/mL were independently
associated with the risk of non-cirrhotic HCC. We
thus suggested that virologic characteristics might 
be similar between cirrhotic and non-cirrhotic HCC
patients.
Role of pre-S deletion in HCC
In addition to the above common viral factors, pre-S
deletion of HBV has recently been shown to be asso-
ciated with the progress of liver disease and the devel-
opment of HCC in HBV carriers. The interactions
among pre-S deletion, PC mutation, and BCP muta-
tion in various stages of chronic HBV infection were
thus investigated in 46 HBV chronic carriers and 106
age-matched carriers with different stages of liver dis-
eases including 38 with chronic hepatitis, 18 with liver
cirrhosis, and 50 with HCC.33 By logistic regression
analysis, patients with pre-S deletion and BCP muta-
tion were significantly associated with the develop-
ment of progressive liver diseases than those without.
Combination of mutations rather than single muta-
tion was associated with the development of progressive
liver diseases, especially in combination with pre-S
deletion. Sequencing analysis showed that the deleted
regions were more often in the 3′ terminus of pre-S1
and the 5′ terminus of pre-S2. Our data indicate that
patients with progressive liver diseases including HCC
have a higher frequency of pre-S deletion.
Summary and Perspectives
Our serial studies strongly indicate that several viral
factors are critically involved in the development of
HCC.37,42–44,46,48,49 However, why these viral factors
contribute to higher risks of HCC development remains
largely unknown. Previous studies suggested the fol-
lowing mechanisms. First, integration of HBV DNA
into host cellular DNA, in some situations, acts to dis-
rupt or promote expression of cellular genes. Second,
truncated pre-S2/S, X, and spliced proteins expressed
from these integrated genes may have a direct effect
on cellular functions and account for their association
with HCC.50 Taken together, more investigations are
needed to clarify the role of these viral factors in each
stage of liver disease progression and in hepatocarcino-
genesis. Furthermore, since host genomic background
also contributes to final pathogenic outcome, integrat-
ing the genetic factors in both host and viral genomes
leading to a predisposition to hepatocarcinogenesis will
help illuminate the critical carcinogenic mechanisms.
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